Community Practice Connections™: 3rd Annual Precision Medicine Through Plasma™: Using Liquid Biopsies in Contemporary Oncology Care

Release Date: February 28, 2020
Expiration Date: February 28, 2021
Media: Internet - based

Activity Overview

Community Practice Connections™: 3rd Annual Precision Medicine Through Plasma™: Using Liquid Biopsies in Contemporary Oncology Care consists of a series of interactive clinical vignettes, short video interviews of leading experts in solid tumors, and short summaries of clinical data related to these clinical vignettes. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Benefits of Participating

• Learn about the benefits of liquid-based molecular testing
• Discuss clinical applications of liquid-based testing in lung, breast, and colon cancers
• See how experts weigh the roles of liquid-based and tissue-based testing

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Guardant Health, Inc., and Novartis Pharmaceuticals Corporation.

Target Audience

This educational activity is intended for medical oncologists, pathologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Assess the relative advantages of currently available liquid-based and tissue-based testing approaches
• Review the capabilities of currently available liquid biopsy technologies
• Appraise the utility of liquid biopsies for different cancers, including non-small cell lung cancer, breast cancer, and gastrointestinal cancers
• Apply clinical evidence on specific testing modalities that may help to individualize treatment protocols for patients with cancer

Faculty, Staff, and Planners’ Disclosures

Faculty

Benjamin P. Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Celgene, Merck, Eli Lilly, Genentech, and Takeda Pharmaceutical Company Limited.

Natasha B. Leighl, MD, MMSc, BSc
Clinician Investigator and Cancer Clinical Research Unit (CCRU)
Princess Margaret Cancer Centre
Associate Professor, Department of Medicine
University of Toronto
Toronto, Ontario

Disclosures: Grant Research Support: AstraZeneca, Array BioPharma, and Guardant Health, Merck Sharp & Dohme (MSD), and Roche; Consultant: Xcovery.

Joseph A. Sparano, MD
Professor of Medicine & Women’s Health
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: Deciphera Pharmaceuticals, Inc. and Prescient Therapeutics; Consultant: AstraZeneca, Celgene Corporation, CStone Pharmaceuticals, Cardinal Health, Inc., Novartis, Pfizer Inc., Genentech/Roche, and Eli Lilly; Shareholder: MetaStat Inc.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.